Separately, Bank of America cut shares of Athersys from a “buy” rating to an “underperform” rating and reduced their price target for the company from $1.00 to $0.25 in a report on Monday, May 23rd.
Athersys Stock Up 3.4 %
Athersys stock opened at $0.26 on Wednesday. The stock has a market capitalization of $68.25 million, a PE ratio of -0.74 and a beta of -1.26. Athersys has a twelve month low of $0.17 and a twelve month high of $1.81. The company has a 50 day moving average of $0.26 and a 200-day moving average of $0.55.
Institutional Trading of Athersys
Institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP lifted its position in shares of Athersys by 109.8% in the fourth quarter. GSA Capital Partners LLP now owns 557,964 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 292,070 shares in the last quarter. Values First Advisors Inc. lifted its position in shares of Athersys by 32.1% in the first quarter. Values First Advisors Inc. now owns 347,876 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 84,471 shares in the last quarter. Perkins Capital Management Inc. lifted its position in shares of Athersys by 151.1% in the fourth quarter. Perkins Capital Management Inc. now owns 59,000 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 35,500 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of Athersys by 232.6% in the second quarter. Green Alpha Advisors LLC now owns 733,487 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 512,984 shares in the last quarter. Finally, Tobias Financial Advisors Inc. bought a new stake in shares of Athersys in the first quarter worth $36,000. Institutional investors own 22.39% of the company’s stock.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
- Get a free copy of the StockNews.com research report on Athersys (ATHX)
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
- Time To Take A Serious Look At Nikola Stock As Production Starts
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.